OBJECTIVE: Polycythemia vera (PV) is characterized by erythrocytosis associated with the presence of the activating JAK2(V617F) mutation in a variable proportion of hematopoietic cells. JAK2(V617F) is detected in other myeloproliferative neoplasms, does not appear to be the PV-initiating event, and its specific role in deregulated erythropoiesis in PV is incompletely understood. We investigated the pathogenesis of PV to characterize abnormal proliferation and apoptosis responses and aberrant oncogenic pathway activation in primary PV erythroid precursors. MATERIALS AND METHODS: Peripheral blood CD34(+) cells isolated from PV patients and healthy controls were grown in liquid culture to expand a population of primary erythroblasts for experiments designed to analyze cellular proliferation, apoptosis, JAK2(V617F) mutation status, cytokine-dependent protein phosphorylation and gene expression profiling using Affymetrix microarrays. RESULTS: The survival and proliferation of PV erythroblasts were growth factor-dependent under strict serum-free conditions requiring both erythropoietin (EPO) and stem cell factor. PV erythroblasts exhibited EPO hypersensitivity and enhanced cellular proliferation associated with increased EPO-mediated extracellular signal-regulated kinases 1 and 2 phosphorylation. EPO-induced AKT phosphorylation was observed in PV but not normal erythroblasts, an effect associated with apoptosis resistance in PV erythroblasts. Analysis of gene expression and oncogenic pathway activation signatures revealed increased RAS (p<0.01) and phosphoinositide-3 kinase (p<0.05) pathway activation in PV erythroblasts. CONCLUSION: Deregulated erythropoiesis in PV involves EPO hypersensitivity and apoptosis resistance of erythroid precursor cells associated with abnormally increased activation of RAS-ERK and phosphoinositide-3 kinase-AKT pathways. These data suggest that investigation of the mechanisms of abnormal RAS and phosphoinositide-3 kinase pathway activation in erythroblasts may contribute to our understanding of the molecular pathogenesis of PV.
OBJECTIVE:Polycythemia vera (PV) is characterized by erythrocytosis associated with the presence of the activating JAK2(V617F) mutation in a variable proportion of hematopoietic cells. JAK2(V617F) is detected in other myeloproliferative neoplasms, does not appear to be the PV-initiating event, and its specific role in deregulated erythropoiesis in PV is incompletely understood. We investigated the pathogenesis of PV to characterize abnormal proliferation and apoptosis responses and aberrant oncogenic pathway activation in primary PV erythroid precursors. MATERIALS AND METHODS: Peripheral blood CD34(+) cells isolated from PV patients and healthy controls were grown in liquid culture to expand a population of primary erythroblasts for experiments designed to analyze cellular proliferation, apoptosis, JAK2(V617F) mutation status, cytokine-dependent protein phosphorylation and gene expression profiling using Affymetrix microarrays. RESULTS: The survival and proliferation of PV erythroblasts were growth factor-dependent under strict serum-free conditions requiring both erythropoietin (EPO) and stem cell factor. PV erythroblasts exhibited EPOhypersensitivity and enhanced cellular proliferation associated with increased EPO-mediated extracellular signal-regulated kinases 1 and 2 phosphorylation. EPO-induced AKT phosphorylation was observed in PV but not normal erythroblasts, an effect associated with apoptosis resistance in PV erythroblasts. Analysis of gene expression and oncogenic pathway activation signatures revealed increased RAS (p<0.01) and phosphoinositide-3 kinase (p<0.05) pathway activation in PV erythroblasts. CONCLUSION: Deregulated erythropoiesis in PV involves EPOhypersensitivity and apoptosis resistance of erythroid precursor cells associated with abnormally increased activation of RAS-ERK and phosphoinositide-3 kinase-AKT pathways. These data suggest that investigation of the mechanisms of abnormal RAS and phosphoinositide-3 kinase pathway activation in erythroblasts may contribute to our understanding of the molecular pathogenesis of PV.
Authors: E Parganas; D Wang; D Stravopodis; D J Topham; J C Marine; S Teglund; E F Vanin; S Bodner; O R Colamonici; J M van Deursen; G Grosveld; J N Ihle Journal: Cell Date: 1998-05-01 Impact factor: 41.582
Authors: Lilian Varricchio; Elena Masselli; Elena Alfani; Angela Battistini; Giovanni Migliaccio; Alessandro Maria Vannucchi; Wenyong Zhang; Damiano Rondelli; James Godbold; Barbara Ghinassi; Carolyn Whitsett; Ronald Hoffman; Anna Rita Migliaccio Journal: Blood Date: 2011-02-25 Impact factor: 22.113
Authors: Chutima Kumkhaek; Wulin Aerbajinai; Wenli Liu; Jianqiong Zhu; Naoya Uchida; Roger Kurlander; Matthew M Hsieh; John F Tisdale; Griffin P Rodgers Journal: Blood Date: 2013-01-17 Impact factor: 22.113
Authors: Juan Li; Dominik Spensberger; Jong Sook Ahn; Shubha Anand; Philip A Beer; Cedric Ghevaert; Edwin Chen; Ariel Forrai; Linda M Scott; Rita Ferreira; Peter J Campbell; Steve P Watson; Pentao Liu; Wendy N Erber; Brian J P Huntly; Katrin Ottersbach; Anthony R Green Journal: Blood Date: 2010-05-20 Impact factor: 22.113
Authors: Edwin Chen; Philip A Beer; Anna L Godfrey; Christina A Ortmann; Juan Li; Ana P Costa-Pereira; Catherine E Ingle; Emmanouil T Dermitzakis; Peter J Campbell; Anthony R Green Journal: Cancer Cell Date: 2010-11-16 Impact factor: 31.743